

1. NAME OF MEDICINAL PRODUCT

SITAGLO-M 50mg/850mg Film-coated Tablet
SITAGLO-M 50mg/1000mg Film-coated Tablet

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SITAGLO-M 50mg/850mg Film-coated Tablet: Each tablet contains 64.25mg of Sitagliptin Phosphate Monohydrate equivalent to 50mg of Sitagliptin and Metformin Hydrochloride 850mg.

SITAGLO-M 50mg/1000mg Film-coated Tablet: Each tablet contains 64.25mg of Sitagliptin Phosphate Monohydrate equivalent to 50mg of Sitagliptin and Metformin Hydrochloride 1000mg.

For the full list of excipients, see section “List of excipients”.

3. PHARMACEUTICAL FORM

Film Coated Tablet

SITAGLO-M 50mg/850mg Film-coated Tablet: Pink colored, capsule shaped, biconvex, film-coated tablets debossed with 'A' on one side and '18' on other side.

SITAGLO-M 50mg/1000mg Film-coated Tablet: Red colored, capsule shaped, biconvex, film-coated tablets debossed with 'A' on one side and '20' on other side.

4. CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

SITAGLO-M is indicated as initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control.

SITAGLO-M is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin.

SITAGLO-M is indicated as part of triple combination therapy with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: metformin, sitagliptin, or a sulfonylurea.

SITAGLO-M is indicated as triple combination therapy with a PPAR γ agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR γ agonist.

SITAGLO-M is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycemic control.

4.2 POSOLOGY AND METHOD OF ADMINISTRATION

The dosage of antihyperglycaemic therapy with SITAGLO-M should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100mg sitagliptin. Initial combination therapy or maintenance of combination therapy should be individualized and left to the discretion of the health care provider.

SITAGLO-M should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal (GI) side effects associated with metformin.

The starting dose of SITAGLO-M should be based on the patient's current regimen. SITAGLO-M should be given twice daily with meals.

Patients inadequately controlled with diet and exercise alone:

If therapy with a combination tablet containing sitagliptin and metformin is considered appropriate for a patient with type 2 diabetes mellitus inadequately controlled with diet and exercise alone, the recommended starting dose is 50mg sitagliptin/500mg metformin hydrochloride twice daily. Patients with inadequate glycaemic control on this dose can be titrated up to 50mg sitagliptin/ 1000mg metformin hydrochloride twice daily.

Patients inadequately controlled on metformin monotherapy:

If therapy with a combination tablet containing sitagliptin and metformin is considered appropriate for a patient inadequately controlled on metformin alone, the recommended starting dose of SITAGLO-M should provide sitagliptin dosed as 50mg twice daily (100mg total daily dose), and the dose of metformin already being taken.

Patients inadequately controlled on sitagliptin monotherapy:

If therapy with a combination tablet containing sitagliptin and metformin is considered appropriate for a patient inadequately controlled on sitagliptin alone, the recommended starting dose of SITAGLO-M is 50mg sitagliptin/ 500mg metformin hydrochloride twice daily. Patients with inadequate control on this dose can be titrated up to 50mg sitagliptin/ 1000mg metformin hydrochloride twice daily. Patients taking sitagliptin monotherapy dose-adjusted for renal impairment should not be switched to SITAGLO-M.

Patients switching from coadministration of sitagliptin and metformin:

For patients switching from sitagliptin coadministered with metformin, SITAGLO-M may be initiated at the dose of sitagliptin and metformin already being taken.

Patients inadequately controlled on dual combination therapy with any two of the following three antihyperglycaemic agents: sitagliptin, metformin or a sulfonylurea:

If therapy with a combination tablet containing sitagliptin and metformin is considered appropriate in this setting, the usual starting dose of SITAGLO-M should provide sitagliptin dosed as 50mg twice daily (100mg total daily dose). In determining the starting dose of the metformin component, the patient's level of glycaemic control and current dose (if any) of metformin should be considered. Gradual dose escalation to reduce the gastrointestinal (GI) side effect associated with metformin should be considered. Patients currently on or initiating a sulfonylurea may require lower sulfonylurea doses to reduce the risk of hypoglycemia.

For patients inadequately controlled on dual combination therapy with the maximal tolerated dose of metformin and a PPAR γ agonist

The dose of SITAGLO-M should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.

For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin

The dose of SITAGLO-M should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken. When SITAGLO-M is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycemia (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

No studies have been performed specifically examining the safety and efficacy of SITAGLO-M in patients previously treated with other oral antihyperglycaemia agents and switched to SITAGLO-M. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycaemic control can occur.

Renal impairment

An eGFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.

The maximum daily dose of metformin should preferably be divided into 2-3 daily doses. Factors that may increase the risk of lactic acidosis should be reviewed before considering initiation of metformin in patients with eGFR < 60 mL/min/1.73m².

If no adequate strength of SITAGLO-M is available, individual monocomponents should be used instead of the fixed dose combination.

eGFR mL/min	Metformin	Sitagliptin
60-89	Maximum daily dose is 3000mg. Dose reduction may be considered in relation to declining renal function.	Maximum daily dose is 100mg.
45-59	Maximum daily dose is 2000mg. The starting dose is at most half of the maximum dose	Maximum daily dose is 100mg.
30-44	Maximum daily dose is 1000mg. The starting dose is at most half of the maximum dose.	Maximum daily dose is 50mg.
<30	Metformin is contraindicated.	Maximum daily dose is 25mg.

Note: SITAGLO-M is available in the strength of 50mg/850mg and 50mg/1000mg. It is not able to deliver all approved dose regimens of Sitagliptin/Metformin Hydrochloride. Other approved dosage forms and strengths of Sitagliptin/Metformin Hydrochloride should be used in such cases.

4.3 CONTRAINDICATIONS

SITAGLO-M (sitagliptin phosphate/metformin HCl) is contraindicated in patients with:

1. Severe renal impairment (eGFR < 30 mL/min/1.73 m²). (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Monitoring of renal function).
2. Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of SITAGLO-M. (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, *Sitagliptin phosphate, Hypersensitivity Reactions* and UNDESIRABLE EFFECTS, *Postmarketing Experience*).
3. Acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis, with or without coma.

SITAGLO-M should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE; Metformin hydrochloride).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

SITAGLO-M should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Pancreatitis: There have been reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis (see UNDESIRABLE EFFECTS), in patients taking sitagliptin. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. Resolution of pancreatitis has been observed after discontinuation of sitagliptin. If pancreatitis is suspected, SITAGLO-M and other potentially suspect medicinal products should be discontinued.

Monitoring of renal function: Metformin and sitagliptin are known to be substantially excreted by the kidney. The risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. SITAGLO-M is contraindicated in severe renal impairment, patients with an eGFR < 30 mL/min/1.73 m² (see

POSODOLOGY AND METHOD OF ADMINISTRATION, CONTRAINDICATIONS and SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Metformin hydrochloride, Lactic acidosis).

Before initiation of therapy with SITAGLO-M and at least annually thereafter, renal function should be assessed. In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and SITAGLO-M discontinued if evidence of renal impairment is present.

Hypoglycemia in Combination with a Sulfonylurea or with Insulin: As is typical with other antihyperglycemic agents, hypoglycemia has been observed when sitagliptin and metformin were used in combination with insulin or a sulfonylurea (see UNDESIRABLE EFFECTS). Therefore, to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia, a lower dose of sulfonylurea or insulin may be considered (see POSODOLOGY AND METHOD OF ADMINISTRATION).

Sitagliptin phosphate

Hypoglycemia in Combination with a Sulfonylurea or with Insulin: In clinical trials of sitagliptin as monotherapy and as part of combination therapy with agents not known to cause hypoglycemia (i.e., metformin or a PPAR γ agonist (thiazolidinedione), rates of hypoglycemia reported with sitagliptin were similar to rates in patients taking placebo. As typical with other antihyperglycemic agents, hypoglycemia has been observed when sitagliptin was used in combination with insulin or a sulfonylurea (see UNDESIRABLE EFFECTS). Therefore, to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia, a lower dose of sulfonylurea or insulin may be considered (see POSODOLOGY AND METHOD OF ADMINISTRATION).

Hypersensitivity Reactions: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with sitagliptin, one of the components of SITAGLO-M. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens- Johnson syndrome. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Onset of these reactions occurred within the first 3 months after initiation of treatment with sitagliptin, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue SITAGLO-M, assess for other potential causes for the event, and institute alternative treatment for diabetes. (See CONTRAINDICATIONS and UNDESIRABLE EFFECTS, *Postmarketing Experience*.)

Bullous Pemphigoid: Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving SITAGLO-M. If bullous pemphigoid is suspected, SITAGLO-M should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.

Severe and Disabling Arthralgia: There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.

Metformin hydrochloride

Lactic Acidosis: Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.

In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.

Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any

conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis.

Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (5 mmol/L) and an increased anion gap and lactate/pyruvate ratio.

The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patient-years). In more than 20,000 patient-years exposure to metformin in clinical trials, there were no reports of lactic acidosis. Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications (see POSOLOGY AND METHOD OF ADMINISTRATION, Recommendations for use in renal impairment). Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient's age. The risk of lactic acidosis may, therefore, be significantly decreased by regular monitoring of renal function in patients taking metformin and by use of the minimum effective dose of metformin. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function (see USE IN THE ELDERLY, Metformin hydrochloride). In addition, metformin should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clear lactate, metformin should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking metformin, since alcohol potentiates the effects of metformin hydrochloride on lactate metabolism. In addition, metformin should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure.

The onset of lactic acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, and resistant bradyarrhythmias with more marked acidosis. The patient and the patient's physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur. Metformin should be withdrawn until the situation is clarified. Serum electrolytes, ketones, blood glucose, and if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of metformin, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug-related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling.

Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).

Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking metformin, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin hydrochloride is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery (see CONTRAINDICATIONS).

Renal function: GFR should be assessed before treatment initiation and regularly thereafter (See Section POSOLOGY AND METHOD OF ADMINISTRATION). Metformin is contraindicated in patients with GFR <30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function (See Section CONTRAINDICATIONS)

Hypoglycemia: Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking β -adrenergic blocking drugs.

Use of concomitant medications that may affect renal function or metformin disposition: Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion (see INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION, Metformin hydrochloride), should be used with caution.

Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials): Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin (see CONTRAINDICATIONS). Therefore, in patients with an eGFR ≥ 30 to <60 mL/min/1.73 m², in patients with a history of hepatic impairment, alcoholism, or heart failure, or in patients who will be administered intra-arterial iodinated contrast, SITAGLO-M should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be acceptable (see POSOLOGY AND METHOD OF ADMINISTRATION).

Hypoxic states: Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on SITAGLO-M therapy, the drug should be promptly discontinued.

Surgical procedures: Use of SITAGLO-M should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as acceptable (see POSOLOGY AND METHOD OF ADMINISTRATION).

Alcohol intake: Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving SITAGLO-M.

Impaired hepatic function: Since impaired hepatic function has been associated with some cases of lactic acidosis, SITAGLO-M should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.

Vitamin B₁₂ levels: Metformin may reduce Vitamin B₁₂ serum levels. The risk of low Vitamin B₁₂ levels increases with increasing metformin dose, treatment duration, and/or in patients with risk factors known to cause Vitamin B₁₂ deficiency. In case of suspicion of Vitamin B₁₂ deficiency (such as anemia or neuropathy), Vitamin B₁₂ serum levels should be monitored. Periodic Vitamin B₁₂ monitoring could be necessary in patients with risk factors for Vitamin B₁₂ deficiency. Metformin therapy should be continued for as long as it is tolerated and not contraindicated and appropriate corrective treatment for Vitamin B₁₂ deficiency provided in line with current clinical guidelines.

Change in clinical status of patients with previously controlled type 2 diabetes: A patient with type 2 diabetes previously well controlled on SITAGLO-M who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, SITAGLO-M must be stopped immediately and other appropriate corrective measures initiated.

Loss of control of blood glucose: When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold SITAGLO-M and temporarily administer insulin. SITAGLO-M may be reinstituted after the acute episode is resolved.

Paediatric use

The safety and efficacy of the addition of sitagliptin in pediatric patients aged 10 to 17 years with type 2 diabetes and inadequate glycemic control on metformin with or without insulin was assessed in two studies over 54 weeks. The addition of sitagliptin (administered as sitagliptin phosphate/metformin HCl or sitagliptin phosphate/metformin HCl XR) was compared to the addition of placebo to metformin or metformin XR.

While superiority of HbA_{1c} reduction was demonstrated for sitagliptin phosphate/metformin HCl or sitagliptin phosphate/metformin HCl XR over metformin at Week 20 in the pooled analysis of these two studies, results from the individual studies were inconsistent. Furthermore, efficacy for sitagliptin phosphate/metformin HCl or sitagliptin phosphate/metformin HCl XR over metformin was not observed at Week 54. Therefore, these results do not support use of sitagliptin phosphate/metformin HCl or sitagliptin phosphate/metformin HCl XR in pediatric subjects (10 to 17 years old) with type 2 diabetes.

In pediatric patients aged 10 to 17 years with type 2 diabetes, the profile of side effects was comparable to that observed in adults.

sitagliptin phosphate/metformin HCl or sitagliptin phosphate/metformin HCl XR have not been studied in pediatric patients under 10 years of age.

Elderly

SITAGLO-M

Because sitagliptin and metformin are substantially excreted by the kidney and because aging can be associated with reduced renal function, SITAGLO-M should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function (See SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Monitoring of Renal Function).

Sitagliptin phosphate

In clinical studies, the safety and effectiveness of sitagliptin in the elderly (≥ 65 years) were comparable to those seen in younger patients (<65 years).

Metformin hydrochloride

Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients.

4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

Sitagliptin and metformin

Coadministration of multiple doses of sitagliptin (50 mg b.i.d.) and metformin (1000 mg b.i.d.) did not meaningfully alter the pharmacokinetics of either sitagliptin or metformin in patients with type 2 diabetes.

Pharmacokinetic drug interaction studies with SITAGLO-M have not been performed; however, such studies have been conducted with the individual components of SITAGLO-M, sitagliptin and metformin.

Sitagliptin phosphate

In drug interaction studies, sitagliptin did not have clinically meaningful effects on the pharmacokinetics of the following: metformin, rosiglitazone, glyburide, simvastatin, warfarin, and oral contraceptives. Based on these data,

sitagliptin does not inhibit CYP isozymes CYP3A4, 2C8, or 2C9. Based on in vitro data, sitagliptin is also not expected to inhibit CYP2D6, 1A2, 2C19 or 2B6 or to induce CYP3A4.

Population pharmacokinetic analyses have been conducted in patients with type 2 diabetes. Concomitant medications did not have a clinically meaningful effect on sitagliptin pharmacokinetics. Medications assessed were those that are commonly administered to patients with type 2 diabetes including cholesterol-lowering agents (e.g., statins, fibrates, ezetimibe), anti-platelet agents (e.g., clopidogrel), antihypertensives (e.g., ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, hydrochlorothiazide), analgesics and non-steroidal anti-inflammatory agents (e.g., naproxen, diclofenac, celecoxib), anti-depressants (e.g., bupropion, fluoxetine, sertraline), antihistamines (e.g., cetirizine), proton-pump inhibitors (e.g., omeprazole, lansoprazole), and medications for erectile dysfunction (e.g., sildenafil).

There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (C_{max} , 18%) of digoxin with the coadministration of sitagliptin. These increases are not considered to be clinically meaningful. Patients receiving digoxin should be monitored appropriately. The AUC and C_{max} of sitagliptin were increased approximately 29% and 68%, respectively, in subjects with coadministration of a single 100-mg oral dose of sitagliptin and a single 600-mg oral dose of cyclosporine, a potent probe inhibitor of p-glycoprotein. The observed changes in sitagliptin pharmacokinetics are not considered to be clinically meaningful.

Metformin hydrochloride

Glyburide: In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decreases in glyburide AUC and C_{max} were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects make the clinical significance of this interaction uncertain.

Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration. Furosemide increased the metformin plasma and blood C_{max} by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the C_{max} and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when coadministered chronically.

Nifedipine: A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that coadministration of nifedipine increased plasma metformin C_{max} and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. T_{max} and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.

Drugs that reduce metformin clearance: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis. Consider the benefits and risks of concomitant use.

Other: Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving SITAGLO-M the patient should be closely observed to maintain adequate glycemic control.

In healthy volunteers, the pharmacokinetics of metformin and propranolol, and metformin and ibuprofen were not affected when coadministered in single-dose interaction studies.

Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.

4.6 FERTILITY, PREGNANCY AND LACTATION

Pregnancy

SITAGLO-M

There are no adequate and well-controlled studies in pregnant women with SITAGLO-M or its individual components; therefore, the safety of SITAGLO-M in pregnant women is not known. SITAGLO-M, like other oral antihyperglycemic agents, is not recommended for use in pregnancy.

No animal studies have been conducted with the combined products in SITAGLO-M to evaluate effects on reproduction. The following data are based on findings in studies performed with sitagliptin or metformin individually.

Sitagliptin phosphate

Sitagliptin was not teratogenic in rats at oral doses up to 250 mg/kg or in rabbits given up to 125 mg/kg during organogenesis (up to 32 and 22 times, respectively, the human exposure based on the recommended daily adult human dose of 100 mg/day). In rats, a slight increase in the incidence of fetal rib malformations (absent, hypoplastic and wavy ribs) was observed at oral doses of 1000 mg/kg/day (approximately 100 times the human exposure based on the recommended daily adult human dose of 100 mg/day). Slight decreases in mean preweaning body weights of both sexes and postweaning body weight gains of males were observed in the offspring of rats given oral dose of 1000 mg/kg/day. However, animal reproduction studies are not always predictive of the human response.

Metformin hydrochloride

Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

Breastfeeding

No studies in lactating animals have been conducted with the combined components of SITAGLO-M. In studies performed with the individual components, both sitagliptin and metformin are secreted in the milk of lactating rats. It is not known whether sitagliptin is excreted in human milk. Therefore, SITAGLO-M should not be used by a woman who is nursing.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Unknown.

4.8 UNDESIRABLE EFFECTS

In placebo-controlled clinical trials, in patients with type 2 diabetes mellitus, the combination of sitagliptin and metformin was generally well tolerated. The overall incidence of side effects reported in patients receiving the combination of sitagliptin and metformin was similar to that reported in patients receiving the combination of placebo and metformin.

Combination Therapy with Sitagliptin and Metformin

Initial Therapy

In a 24-week placebo-controlled factorial study of initial therapy with sitagliptin 50 mg twice daily in combination with metformin at 500 or 1000 mg twice daily, the drug-related adverse reactions reported in $\geq 1\%$ of patients receiving combination therapy (and greater than in patients receiving placebo) are shown in Table 1.

Table 1 Initial Therapy with Combination of Sitagliptin and Metformin: Drug-Related Adverse Reactions Reported in $\geq 1\%$ of Patients Receiving Combination Therapy (and Greater than in Patients Receiving Placebo)[†]				
	Number of Patients (%)			
	Placebo	Sitagliptin 100 mg q.d.	Metformin 500 or 1000 mg b.i.d. ^{† †}	Sitagliptin 50 mg b.i.d. + Metformin 500 or 1000 mg b.i.d. ^{† †}
	N = 176	N = 179	N = 364	N = 372
Diarrhea	2 (1.1)	0 (0.0)	12 (3.3)	13 (3.5)
Nausea	1 (0.6)	0 (0.0)	9 (2.5)	6 (1.6)
Dyspepsia	0 (0.0)	0 (0.0)	4 (1.1)	5 (1.3)
Flatulence	0 (0.0)	0 (0.0)	2 (0.5)	5 (1.3)
Vomiting	0 (0.0)	0 (0.0)	1 (0.3)	4 (1.1)
Headache	0 (0.0)	1 (0.6)	4 (1.1)	5 (1.3)
Hypoglycemia	0 (0.0)	1 (0.6)	2 (0.5)	4 (1.1)

[†] Intent-to-treat population

^{† †} Data pooled for the patients given the lower and higher doses of metformin.

Add-on Combination Therapy to Metformin

In a 24-week placebo-controlled study of sitagliptin added to ongoing metformin therapy, 464 patients on metformin were treated with sitagliptin 100 mg once daily and 237 patients were given placebo with metformin. The only drug-related adverse reaction reported that occurred with an incidence of $\geq 1\%$ and higher than placebo in patients receiving sitagliptin and metformin was nausea (100 mg sitagliptin and metformin; 1.1%, placebo and metformin, 0.4%).

Hypoglycemia and Gastrointestinal Adverse Experiences

In the placebo-controlled studies of combination therapy with sitagliptin and metformin, the incidence of hypoglycemia (regardless of investigator assessment of causality) reported in patients treated with the combination of sitagliptin and metformin was similar to that reported for patients treated with metformin and placebo. The incidences of pre-specified gastrointestinal adverse experiences in patients treated with the combination of sitagliptin and metformin were similar to those reported for patients treated with metformin alone. See Table 2.

Table 2 Hypoglycemia and Pre-specified Gastrointestinal Adverse Experiences (Regardless of Investigator Assessment of Causality) Reported in Patients Receiving Combination Therapy†						
	Number of Patients (%)					
	Study of Sitagliptin and Metformin as Initial Therapy				Study of Sitagliptin as Add-on to Metformin	
	Placebo	Sitagliptin 100 mg q.d.	Metformin 500 or 1000 mg b.i.d. † †	Sitagliptin 50 mg b.i.d. + Metformin 500 or 1000 mg b.i.d. † †	Placebo and Metformin ≥ 1500 mg daily	Sitagliptin 100 mg q.d. and Metformin ≥ 1500 mg daily
	N = 176	N = 179	N = 364	N = 372	N = 237	N = 464
Hypoglycemia	1 (0.6)	1 (0.6)	3 (0.8)	6 (1.6)	5 (2.1)	6 (1.3)
Diarrhea	7 (4.0)	5 (2.8)	28 (7.7)	28 (7.5)	6 (2.5)	11 (2.4)
Nausea	2 (1.1)	2 (1.1)	20 (5.5)	18 (4.8)	2 (0.8)	6 (1.3)
Vomiting	1 (0.6)	0 (0.0)	2 (0.5)	8 (2.1)	2 (0.8)	5 (1.1)
Abdominal Pain†	4 (2.3)	6 (3.4)	14 (3.8)	11 (3.0)	9 (3.8)	10 (2.2)

† In the study of initial therapy, Abdominal Discomfort was included with Abdominal Pain

† † Data pooled for the patients given the lower and higher doses of metformin.

In all studies, adverse experiences of hypoglycemia were based on all reports of symptomatic hypoglycemia; a concurrent glucose measurement was not required.

Sitagliptin in Combination with Metformin and a Sulfonylurea

In a 24-week placebo-controlled study of sitagliptin 100 mg daily added to ongoing combination treatment with glimepiride ≥ 4 mg daily and metformin ≥ 1500 mg daily, the drug-related adverse reactions reported in ≥ 1% of patients treated with sitagliptin (N=116) and more commonly than in patients treated with placebo (N=113) were hypoglycemia (sitagliptin, 13.8%; placebo, 0.9%) and constipation (1.7%, 0.0%).

Sitagliptin in Combination with Metformin and a PPAR γ Agonist

In a placebo-controlled study of sitagliptin 100 mg daily added to ongoing combination treatment with metformin and rosiglitazone, the drug-related adverse reactions reported through the primary time point at Week 18 in ≥ 1% of patients treated with sitagliptin (N=170) and more commonly than in patients treated with placebo (N=92) were: headache (sitagliptin, 2.4%; placebo, 0.0%), diarrhea (1.8%, 1.1%), nausea (1.2%, 1.1%), hypoglycemia (1.2%, 0.0%), and vomiting (1.2%, 0.0%). Through Week 54, the drug-related adverse reactions reported in ≥ 1% of patients treated with sitagliptin and more commonly than in patients treated with placebo were: headache (2.4%, 0.0%), hypoglycemia (2.4%, 0.0%), upper respiratory tract infection (1.8%, 0.0%),

nausea (1.2%, 1.1%), cough (1.2%, 0.0%), fungal skin infection (1.2%, 0.0%), peripheral edema (1.2%, 0.0%), and vomiting (1.2%, 0.0%).

Sitagliptin in Combination with Metformin and Insulin

In a 24-week placebo-controlled study of sitagliptin 100 mg added to ongoing combination treatment with metformin $\geq$ 1500 mg daily and stable-dose insulin, the only drug-related adverse reaction reported in $\geq$ 1% of patients treated with sitagliptin (N=229) and more commonly than in patients treated with placebo (N=233) was hypoglycemia (sitagliptin, 10.9%; placebo, 5.2%). In another 24-week study of patients receiving sitagliptin as add-on therapy while undergoing insulin intensification (with or without metformin), the only drug-related adverse reaction reported in $\geq$ 1% in patients treated with sitagliptin and metformin and more commonly than in patients treated with placebo and metformin was vomiting (sitagliptin and metformin, 1.1%; placebo and metformin, 0.4%).

Pancreatitis

In a pooled analysis of 19 double-blind clinical trials that included data from 10,246 patients randomized to receive sitagliptin 100 mg/day (N=5429) or corresponding (active or placebo) control (N=4817), the incidence of non-adjudicated acute pancreatitis events was 0.1 per 100 patient-years in each group (4 patients with an event in 4708 patient-years for sitagliptin and 4 patients with an event in 3942 patient-years for control). See also TECOS Cardiovascular Safety Study, below. (See SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Pancreatitis)

With the combination of sitagliptin and metformin, no clinically meaningful changes in vital signs or in ECG (including in QTc interval) were observed.

Adverse Reactions Reported with Sitagliptin

The most common adverse experience in sitagliptin monotherapy reported regardless of investigator assessment of causality in $\geq$ 5% of patients and more commonly than in patients given placebo was nasopharyngitis.

*Adverse Reactions Reported with Metformin**

The following adverse reactions may occur under treatment with metformin. Frequencies are defined as follows: very common $\geq$ 1/10; common $\geq$ 1/100 - <1/10; uncommon $\geq$ 1/1,000 - <1/100; rare $\geq$ 1/10,000 - <1/1,000; very rare <1/10,000. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Metabolism and nutrition disorders:

Common:

Vitamin B12 decreases/deficiency (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

Very rare:

Lactic acidosis (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE)

Nervous system disorders:

Common:

Taste disturbance

Gastrointestinal disorders:

Very common:

Gastrointestinal disorders such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. To prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. A slow increase of the dose may also improve gastrointestinal tolerability.

Hepatobiliary disorders:

Very rare:

Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.

Skin and subcutaneous tissue disorders:

Very rare:

Skin reactions such as erythema, pruritus, urticaria

TECOS Cardiovascular Safety Study

TECOS Cardiovascular Safety Study: The Trial Evaluating Cardiovascular Outcomes with sitagliptin (TECOS) included 7,332 patients treated with sitagliptin, 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL/min/1.73 m²), and 7,339 patients treated with placebo in the intention-to-treat population. Both treatments were added to usual care targeting regional standards for HbA1c and CV risk factors. The overall incidence of serious adverse events in patients receiving sitagliptin was similar to that in patients receiving placebo.

In the intention-to-treat population, among patients who were using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 2.7 % in sitagliptin-treated patients and 2.5 % in placebo-treated patients; among patients who were not using insulin and/or a sulfonylurea at baseline, the incidence of severe hypoglycaemia was 1.0 % in sitagliptin-treated patients and 0.7 % in placebo-treated patients. The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptin-treated patients and 0.2 % in placebo-treated patients.

Pediatric population

In a pooled analysis of two placebo-controlled clinical studies with Sitagliptin + Metformin and Sitagliptin + Metformin XR in pediatric patients aged 10 to 17 years with type 2 diabetes, the drug-related adverse reactions reported through the 54-week treatment period in $\geq 1\%$ of patients in the Sitagliptin-Metformin/ Sitagliptin-Metformin XR group (N=107) and more commonly than in patients in the Metformin/Metformin XR group (N=113) were diarrhea (Sitagliptin + Metformin/ Sitagliptin + Metformin XR, 2.8%; Metformin/Metformin XR, 0.9%), nausea (2.8%, 0.9%), and hypoglycemia (6.5%, 3.5%).

The profile of side effects was comparable to that observed in adults. There were no clinically relevant differences between the Sitagliptin + Metformin/ Sitagliptin + Metformin XR and Metformin/Metformin XR groups through Week 54 in laboratory safety endpoints, vital signs, indices of adiposity, or growth and development endpoints.

Postmarketing Experience:

Additional adverse reactions have been identified during postmarketing use of Sitagliptin/Metformin or sitagliptin, one of the components of Sitagliptin/Metformin. These reactions have been reported when Sitagliptin/Metformin or sitagliptin have been used alone and/or in combination with other antihyperglycemic agents. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin conditions including Stevens-Johnson syndrome (see CONTRAINDICATIONS and SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Sitagliptin phosphate, Hypersensitivity Reactions); acute pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing pancreatitis (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Pancreatitis); worsening renal function, including acute renal failure (sometimes requiring dialysis); bullous pemphigoid (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Bullous Pemphigoid); severe and disabling arthralgia (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Severe and Disabling Arthralgia); upper respiratory tract infection; nasopharyngitis; constipation; vomiting; headache; myalgia; pain in extremity; back pain; pruritus; thrombocytopenia.

Laboratory Test Findings

Sitagliptin phosphate

The incidence of laboratory adverse experiences was similar in patients treated with sitagliptin and metformin compared to patients treated with placebo and metformin. Across clinical studies, a small increase in white blood cell count (approximately 200 cells/microL difference in WBC vs placebo; mean baseline WBC approximately 6600 cells/microL) was observed due to a small increase in neutrophils. This observation was seen in most but not all studies. This change in laboratory parameters is not considered to be clinically relevant.

Metformin hydrochloride

In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum Vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or Vitamin B12 supplementation (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Metformin hydrochloride).

4.9 OVERDOSE

Sitagliptin phosphate

During controlled clinical trials in healthy subjects, single doses of up to 800 mg sitagliptin were generally well tolerated. Minimal increases in QTc, not considered to be clinically relevant, were observed in one study at a dose of 800 mg sitagliptin (see Mechanism of Action, Pharmacodynamics, Cardiac Electrophysiology). There is no experience with doses above 800 mg in clinical studies. In Phase I multiple-dose studies, there were no dose-related clinical adverse reactions observed with sitagliptin with doses of up to 600 mg per day for periods of up to 10 days and 400 mg per day for periods of up to 28 days.

In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy if required.

Sitagliptin is modestly dialyzable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour hemodialysis session. Prolonged hemodialysis may be considered if clinically appropriate. It is not known if sitagliptin is dialyzable by peritoneal dialysis.

Metformin hydrochloride

Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Metformin hydrochloride). Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.

5. PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Drugs used in diabetes, Combinations of oral blood glucose lowering drugs, ATC code: A10BD07

Sitagliptin phosphate

General

In patients with type 2 diabetes, administration of single oral doses of sitagliptin leads to inhibition of DPP-4 enzyme activity for a 24-hour period, resulting in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, increased plasma levels of insulin and C-peptide, decreased glucagon concentrations, reduced fasting glucose, and reduced glucose excursion following an oral glucose load or a meal.

In Phase III clinical studies of 18- and 24-week duration, treatment with sitagliptin 100 mg daily in patients with type 2 diabetes significantly improved beta cell function, as assessed by several markers, including HOMA- β (Homeostasis Model Assessment- β), proinsulin to insulin ratio, and measures of beta cell responsiveness from the frequently-sampled meal tolerance test. In Phase II studies, sitagliptin 50 mg twice daily provided similar glycemic efficacy compared to sitagliptin 100 mg once daily.

In a randomized, placebo-controlled, double-blind, double-dummy, four-period crossover two-day study in healthy adult subjects, the effects on post-meal plasma concentrations of active and total GLP-1 and glucose after coadministration of sitagliptin and metformin were compared with those after administration of sitagliptin alone, metformin alone or placebo, each administered for two days. The incremental 4-hour post-meal weighted mean active GLP-1 concentrations were increased approximately 2-fold after either administration of sitagliptin alone or metformin alone compared with placebo. The effect on active GLP-1 concentrations after coadministration of sitagliptin and metformin were additive, with active GLP-1 concentrations increased by approximately 4-fold compared with placebo. Sitagliptin alone increased only active GLP-1 concentrations, reflecting inhibition of DPP-4, whereas metformin alone increased active and total GLP-1 concentrations to a similar extent. These data are consistent with different mechanisms for the increase in active GLP-1 concentrations. Results from the study also demonstrated that sitagliptin, but not metformin, enhances active GIP concentrations.

In studies with healthy subjects, sitagliptin did not lower blood glucose or cause hypoglycemia, suggesting that the insulinotropic and glucagon suppressive actions of the drug are glucose dependent.

Effects on blood pressure

In a randomized, placebo-controlled crossover study in hypertensive patients on one or more anti-hypertensive drugs (including angiotensin-converting enzyme inhibitors, angiotensin-II antagonists, calcium-channel blockers, beta-blockers and diuretics), coadministration with sitagliptin was generally well tolerated. In these patients, sitagliptin had a modest blood pressure lowering effect; 100 mg per day of sitagliptin reduced 24-hour mean ambulatory systolic blood pressure by approximately 2 mmHg, as compared to placebo. Reductions have not been observed in subjects with normal blood pressure.

Cardiac Electrophysiology

In a randomized, placebo-controlled crossover study, 79 healthy subjects were administered a single oral dose of sitagliptin 100 mg, sitagliptin 800 mg (8 times the recommended dose), and placebo. At the recommended dose of 100 mg, there was no effect on the QTc interval obtained at the peak plasma concentration, or at any other time during the study. Following the 800-mg dose, the maximum increase in the placebo-corrected mean change in QTc from baseline at 3 hours postdose was 8.0 msec. This small increase was not considered to be clinically significant. At the 800-mg dose, peak sitagliptin plasma concentrations were approximately 11 times higher than the peak concentrations following a 100-mg dose.

In patients with type 2 diabetes administered sitagliptin 100 mg (N=81) or sitagliptin 200 mg (N=63) daily, there were no meaningful changes in QTc interval based on ECG data obtained at the time of expected peak plasma concentration.

Therapeutic Class

Sitagliptin phosphate/metformin HCl combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Sitagliptin phosphate

Sitagliptin phosphate is an orally-active, potent, and highly selective inhibitor of the dipeptidyl peptidase 4 (DPP-4) enzyme for the treatment of type 2 diabetes. The DPP-4 inhibitors are a class of agents that act as incretin enhancers. By inhibiting the DPP-4 enzyme, sitagliptin increases the levels of two known active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP). The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. This mechanism is unlike the mechanism seen with sulfonylureas; sulfonylureas cause insulin release even when glucose levels are low, which can lead to sulfonylurea-induced hypoglycemia in patients with type 2 diabetes and in normal subjects. Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations. Sitagliptin differs in chemical structure and pharmacological action from GLP-1 analogues, insulin, sulfonylureas or meglitinides, biguanides, peroxisome proliferator-activated receptor gamma (PPAR γ) agonists, alpha-glucosidase inhibitors, and amylin analogues.

Metformin hydrochloride

Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Metformin hydrochloride) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

Mechanism of action

SITAGLO-M

SITAGLO-M combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.

Sitagliptin phosphate

Sitagliptin phosphate is a member of a class of oral antihyperglycemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors, which improve glycemic control in patients with type 2 diabetes by enhancing the levels of active incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. Treatment with GLP-1 or with DPP-4 inhibitors in animal models of type 2 diabetes has been demonstrated to improve beta cell responsiveness to glucose and stimulate insulin biosynthesis and release. With higher insulin levels, tissue glucose uptake is enhanced. In addition, GLP-1 lowers glucagon secretion from pancreatic alpha

cells. Decreased glucagon concentrations, along with higher insulin levels, lead to reduced hepatic glucose production, resulting in a decrease in blood glucose levels. The effects of GLP-1 and GIP are glucose-dependent. When blood glucose concentrations are low, stimulation of insulin release and suppression of glucagon secretion by GLP-1 are not observed. For both GLP-1 and GIP, stimulation of insulin secretion is enhanced as glucose rises above normal concentrations. GLP-1 does not impair the normal glucagon response to hypoglycemia. The activity of GLP-1 and GIP is limited by the DPP-4 enzyme, which rapidly hydrolyzes the incretin hormones to produce inactive products. Sitagliptin prevents the hydrolysis of incretin hormones by DPP-4, thereby increasing plasma concentrations of the active forms of GLP-1 and GIP. By enhancing active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in a glucose-dependent manner. This glucose dependent mechanism is unlike the mechanism seen with sulfonylureas where insulin is released even when glucose levels are low, which can lead to hypoglycemia in patients with type 2 diabetes and in normal subjects. In patients with type 2 diabetes with hyperglycemia, these changes in insulin and glucagon levels lead to lower hemoglobin A1c (HbA1c) and lower fasting and postprandial glucose concentrations. Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations.

Metformin hydrochloride

Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Metformin hydrochloride) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.

5.2 PHARMACOKINETIC PROPERTIES

Sitagliptin phosphate/metformin HCl

The results of a definitive bioequivalence study in healthy subjects demonstrated that the sitagliptin/metformin hydrochloride 50 mg/500 mg and 50 mg/1000 mg combination tablets are bioequivalent to coadministration of corresponding doses of sitagliptin phosphate and metformin hydrochloride as individual tablets.

Because bioequivalence is demonstrated at the lowest and highest combination tablet dose strengths available, bioequivalence is conferred to the (sitagliptin/metformin) 50 mg/850 mg fixed dose combination (FDC) tablet.*

Absorption

Sitagliptin phosphate

The absolute bioavailability of sitagliptin is approximately 87%. Coadministration of a high-fat meal with sitagliptin phosphate had no effect on the pharmacokinetics of sitagliptin.

Metformin hydrochloride

The absolute bioavailability of a metformin hydrochloride 500 mg tablet given under fasting conditions is approximately 50-60%. Studies using single oral doses of metformin hydrochloride tablets 500 mg to 1500 mg, and 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alternation in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C_{max}), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T_{max}) following administration of a single 850-mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.

Distribution

Sitagliptin phosphate

The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 liters. The fraction of sitagliptin reversibly bound to plasma proteins is low (38%).

Metformin hydrochloride

The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride tablets 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin hydrochloride tablets, steady state plasma concentrations of metformin are reached within 24-48 hours and are generally <1 mcg/mL. During controlled clinical trials of metformin, maximum metformin plasma levels did not exceed 5 mcg/mL, even at maximum doses.

Biotransformation

Sitagliptin phosphate

Sitagliptin is primarily eliminated unchanged in urine, and metabolism is a minor pathway. Approximately 79% of sitagliptin is excreted unchanged in the urine.

Following a [^{14}C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin. In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.

Metformin hydrochloride

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.

Elimination

Sitagliptin phosphate

Following administration of an oral [^{14}C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. The apparent terminal $t_{1/2}$ following a 100-mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min.

Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. The clinical relevance of hOAT-3 in sitagliptin transport has not been established. Sitagliptin is also a substrate of p-glycoprotein, which may also be involved in mediating the renal elimination of sitagliptin. However, cyclosporine, a p-glycoprotein inhibitor, did not reduce the renal clearance of sitagliptin.

Metformin hydrochloride

Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately

6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

Special populations

Type 2 Diabetes

Sitagliptin phosphate

The pharmacokinetics of sitagliptin in patients with type 2 diabetes are generally similar to those in healthy subjects.

Metformin hydrochloride

In the presence of normal renal function, there are no differences between single- or multiple-dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects, nor is there any accumulation of metformin in either group at usual clinical doses.

Renal Impairment

Sitagliptin phosphate

An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal impairment with eGFR of 30 to $<45 \text{ mL/min/1.73 m}^2$, and an approximately 4-fold increase was observed in patients with severe renal impairment ($\text{eGFR} < 30 \text{ mL/min/1.73 m}^2$) including patients with end-stage renal disease (ESRD) on hemodialysis, as compared to subjects with normal renal function.

Metformin hydrochloride

In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged, and the renal clearance is decreased (see CONTRAINDICATIONS and SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

Hepatic Impairment

Sitagliptin phosphate

In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), mean AUC and C_{max} of sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100-mg dose of sitagliptin phosphate. These differences are not considered to be clinically meaningful.

There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score >9). However, because sitagliptin is primarily renally eliminated, severe hepatic impairment is not expected to affect the pharmacokinetics of sitagliptin.

Metformin hydrochloride

No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment.

Gender

Sitagliptin phosphate

Gender had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data.

Metformin hydrochloride

Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analyzed according to gender. Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin was comparable in males and females.

Elderly

Sitagliptin phosphate

Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects.

Metformin hydrochloride

Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half life is prolonged, and C_{max} is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.

Paediatric population

The pharmacokinetics of sitagliptin (single dose of 50 mg, 100 mg or 200 mg) were investigated in pediatric patients (10 to 17 years of age) with type 2 diabetes. In this population, the dose-adjusted AUC of sitagliptin in plasma was approximately 18% lower compared to adult patients with type 2 diabetes for a 100 mg dose. This is not considered to be a clinically meaningful difference based on the flat PK/PD relationship between the dose of 50 mg and 100 mg in adults.

No studies with sitagliptin have been performed in pediatric patients < 10 years of age.

Race

Sitagliptin phosphate

Race had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data, including subjects of white, Hispanic, black, Asian, and other racial groups.

Metformin hydrochloride

No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n=249), blacks (n= 51), and Hispanics (n=24).

Body Mass Index (BMI)

Sitagliptin phosphate

Body mass index (BMI) had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline cellulose, polyvinylpyrrolidone, Sodium laurilsulfate, croscarmellose sodium, sodium stearyl fumarate.

The film coating contains polyvinyl alcohol, macrogol/ PEG, titanium dioxide, talc, iron oxide red, black iron oxide

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Please refer to expiry date on the outer carton.

6.4 Special precautions for storage

Do not store above 30°C.

6.5 Nature and contents of container

Pack sizes available:

- PVC/PE/PVDC-Aluminium Opaque Blister of 14 tablets. Such 4 blister are packed in carton along with pack insert.
- Alu-Alu blister of 7 tablets. Such 4 blister are packed in carton along with pack insert.
- HDPE Bottle of 30 tablets with silica gel bag 1 gm. Such 1 HDPE bottle is packed in carton along with pack insert.

6.6 Special precautions for disposal and other handling

No special requirements.

MANUFACTURER:

RV Lifesciences Limited

Plot No. H-19, MIDC, Waluj,
Chhatrapati Sambhajnagar 431133,
Maharashtra State, India.

DATE OF REVISION

13/07/2026